An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated
